Abstract A large proportion of breast cancers expresses the estrogen receptor alpha (ERa) and are dependent on estrogens for their proliferation and survival. The tumor suppressor TP53 encodes the p53 protein, an important mediator of the anti-proliferative and apoptotic effects of several treatments used for breast cancer. A significant proportions of breast tumors (20-30%) carry mutations in TP53 gene and these mutations are associated with poor survival and poor response to several types of chemotherapeutic treatments. While there is mounting evidence for functional interactions between p53 and ERa pathways in breast and other tissues, the impact of these interactions on response to chemotherapy and anti-hormone treatments remain largely unknown. Here, using estrogen-dependent breast cancer cell lines with different p53 status, we show that estrogens, through ERa, influence p53 protein levels and activities. Estrogen deprivation reduced, while estradiol increased p53 levels, in a time and dose-dependent manner. Both wild-type and endogenously expressed mutant p53 proteins were affected. This reduction in p53 protein levels resulted in reduced p53-dependent responses induced by DNA damage in p53 wild-type cells, lowering the capacity of doxorubicine to induce apoptosis. The p53 response appeared to be quantitatively but not qualitatively affected. These results suggest that ERa activity is required for a strong p53 response in estrogen-dependent breast cancer cells. These results are in line with previous observations that we made in a clinical series, where a larger effect of TP53 mutation status was found for patient survival in cases with progesterone receptor positive status, a marker of a functional ERa pathway. It would thus be important to further characterize the influence of ERa pathway on the predictive value of TP53 mutation status in specifically designed clinical trials, as it may open perspectives for improving breast cancer treatment.
Introduction
The tumor suppressor gene TP53 encodes the p53 protein, a stress-induced transcription factor that exerts anti-proliferative activities through the regulation of genes involved in the control of apoptosis, cell cycle checkpoints, and senescence [1] . Since TP53 constitutes a major barrier to cancer development it is frequently mutated in various types of human cancers [2] . In breast cancer, TP53 mutations are associated with poor prognosis and several studies have reported an association with poor response to different types of chemotherapy drugs [3] .
The estrogen receptor ERa is a member of the nuclear receptor family of transcription factors that mediates the effect of estrogens through genomic (i.e., regulation of gene expression requiring specific co-regulator proteins) and nongenomic activities that results in the control of cell growth, survival, differentiation, apoptosis, and angiogenesis [4] . Nongenomic activities include rapid cellular signaling by direct interaction of cytoplasmic ERa with a variety of trans-membrane growth factor receptors such as EGFR or HER2 [5, 6] .
Several lines of evidence suggest that p53 and ERa can influence each other activities through different mechanisms. Complexes between p53 and ERa proteins have been described that can modulate their stability [7, 8] . ERa has been shown to control p53 mRNA expression [9, 10] and vice versa [11, 12] . p53 can also down regulate ERaresponsive genes by interfering with the binding of ERa to its response element (RE) [13] [14] [15] , and reciprocally, ERa can repress p53 function [16] [17] [18] . Positive regulation of ERa and p53 may also cooperate in the induction of some genes through p53 and ERa RE-half-sites located in promoter regions [19] . Despite these studies, several inconsistent results were reported and the nature, context (ligand-dependent or independent), and biological impacts of these interactions remain to be elucidated.
It is well established that p53 participates in the antiproliferative and apoptotic activities of several anti-cancer drugs that damage DNA, that may account for its prognostic and predictive values in breast cancer [20] . In a large series of 1,794 patients with breast cancers, we previously observed that the prognostic value of TP53 mutation status was stronger in progesterone receptor (PR) positive cases [21] . Since PR expression is a marker for a functional estrogen receptor pathway, these results suggested that a functional ERa pathway may be required for an efficient p53 response in estrogen-dependent breast cancer. To test this hypothesis in cellular models, here we used estrogendependent breast cancer cell lines with different TP53 status to investigate how estrogens may influence p53 dependent biological responses.
Materials and methods
Cell lines and treatments MN1 (p53WT) and MDD2 (p53MUT) cells are isogenic cell lines derived from MCF-7 cells that have been established in 1992 (kindly provided by M. Oren, Weizmann Institute). MDD2 cells are stably transfected with a p-CMV-DD plasmid expressing a p53 mini protein that contains the first 14 and last 89 amino acids of the mouse p53 protein [22] . This mini p53 protein has strong dominant negative activity due to its hetero-oligomerisation with the endogenous p53 protein. This results in the over expression of an inactive p53 protein in MDD2 cells. MN1 cells were similarly generated by transfection of the control insert-free plasmid followed by G418 selection. MN1 and MCF-7 cells have a similar p53 response when treated with the DNA-damaging agent doxorubicin or with estradiol (not shown). These cells were maintained in DMEM (Invitrogen) containing 10% FBS, 2% L-glutamine-penicillin-streptomycin solution stabilized (Sigma) and 0.4 mg/ml geneticin (Invitrogen). ZR-75-1 (p53WT) and T-47D (p53MUT, p.L194F) cells were provided by Dr Theillet and BT-474 (p53MUT, p.E285K) by Dr Puisieux. These cells were maintained in RPMI 1640 (Invitrogen). All cells were cultured at 37°C at 5% CO 2 . For estrogenfree (EF) conditions, cells were cultured in phenol red-free medium (DMEM/F12-Gibco and RPMI 1640-Invitrogen), supplemented with 10% charcoal-stripped dextrantreated serum (HyClone), and other components as indicated above. 17b-estradiol (E2) and doxorubicin (DOX) were purchased from Sigma.
Cell cycle and apoptosis analyses by flow cytometry DNA synthesis was assessed by BrdU (BD-Pharmingen) incorporation and DNA was stained with PI (Sigma) following standard procedures. Cells were fixed with 70% ethanol, DNA denatured with HCl and BrdU revealed with a monoclonal anti-BrdU antibody (BD-Pharmingen). Apoptosis was measured with FITC-Annexin V (BD-Biosciences) following manufacturer's instructions. Data acquisition and analysis were done on a FACS BDLSRII machine using Cell-Quest software. Each experiment was repeated at least twice.
Gene silencing siRNA directed against ESR1 (ERa, ID:42835), TP53 (ID:106141), and scramble RNA (scr) which do not recognize any human mRNA (ID:4611) were purchased from Ambion. siRNAs were transfected into cells with HiPerfect (Quiagen) according to the manufacturer's protocol. ERa and p53 mRNA and protein levels were monitored by qPCR and, Western-blot, respectively.
b-galactosidase assay
Cells were cultured for 48 h in EF medium before transfection, by using FuGene6 reagent (Roche), of p53 reporter plasmid, pRGCDFosLacZ, containing the RGC (Ribosomal Gene Cluster) p53 binding site upstream of the b-galactosidase. 24 h after transfection, different concentrations of E2 were added for 24 h and b-galactosidase activity was measured using b-Galactosidase Enzyme Assay (Promega) according to the manufacturer's instructions.
Protein analyses
Protein extracts were prepared by lyzing cells with RIPAlike buffer (250 mM NaCl, 50 mM Tris-HCl pH7.4, 0.1% SDS, 2 mM DTT, and 0.5% Igepal) containing proteases inhibitors (Complete-Mini, Roche) and phosphatase inhibitors (HALT TM PhosphataseInhibitor Cocktail, PIERCE).
Equal amounts of total proteins were separated on a 10% SDS-PAGE gel and transferred to a PVDF-membrane (Roche). Antibodies and dilutions used are listed in Supplementary q-PCR analysis Total RNA was isolated using the Nucleospin-RNAII kit (Macherey-Nagel) and cDNA was produced by using the SuperScriptII Reverse-Transcriptase (Invitrogen) and random primers (Promega) following manufacturer's instructions. Real-time PCR was carried out in a Stratagene Mx3000 using SyBrGreen mixture (Quiagen) and primers. PCR conditions were as follows: 95°C, 15 min (1cycle); 94°C, 15 s and 60°C, 30 s (50cycles); 72°C, 30 s (1cycle). Primers are listed in Supplementary Table 2 . PCR for each gene fragment was performed in triplicate, and each primer set was repeated 2 or 3 times. The relative mRNA levels were calculated using the DDCt method with the endogenous 28S mRNA as normalizer.
Statistical and densitometry analyses
Statistical analyses were performed using student's t-test, assuming equal variance, and P value was calculated based on two-tailed test. A P value of \0.05 was considered statistically significant (indicated as * in figures, and ** when P value \0.01). Densitometry analyses of Westernblots were performed with the public domain NIH Image program available at: http://rsb.info.nih.gov/nih-image.
Results
Estrogens' impact on wild-type and mutant p53 protein levels Five estrogen-dependent breast cancer cell lines with different p53 status were used in this study, including an isogenic model (MN1 and MDD2) derived from MCF-7 cells (see ''Materials and methods'' section). When maintained for at least 48 h in an estrogen-free (EF) medium, all cell lines showed a reduced proliferation ( Supplementary  Fig. 1A ) and accumulation in G1 phase (as shown for MN1 and MDD2 cells in Supplementary Fig. 1B ). The mRNA expression of the ERa target gene, TFF1, was also significantly reduced, indicating a reduction in ERa genomic activity ( Supplementary Fig. 1C ). In these conditions, p53 protein expression was reduced in all cells expressing an endogenous protein (Fig. 1A) , from 1.5-fold change in T-47D to 2.5-fold change in BT-474 ( Supplementary  Fig. 1D ). In contrast, TP53 mRNA expression was not reduced and even slightly up-regulated (Fig. 1B) . Protein levels were further decreased when cultured for a longer time in EF conditions reaching a plateau at 8 days, as observed in MN1 (Supplementary Fig. 2 ). The decrease in p53 protein levels under estrogen deprivation was confirmed by immuno-fluorescence assays in MN1 cells (Fig. 1C) and showed that both cytoplasmic and nuclear levels of p53 were decreased to undetectable levels in EF conditions.
Since basal p53 protein levels are known to be controlled through degradation by the proteasome [23] , we tested whether inhibiting the proteasome could restore p53 levels in estrogen-deprived conditions. The proteasome inhibitor lactacystin was added for 8 h to MN1 and ZR-75-1 cells cultured in EF medium for 40 h. As shown in Fig. 1D , lactacystin treatment caused a strong increase in p53 protein levels. Thus, blocking the proteasome increased wild-type p53 protein levels in E2-deprived cells as in normal conditions.
To verify that this effect on p53 levels was due to the removal of estrogens and not other steroids, 15nM 17b-estradiol (E2) was added for 48 h on cells cultured in EF medium. These conditions activated ERa genomic activity as shown by an increase in TFF1 expression ( Supplementary  Fig. 1C ). p53 protein levels were increased by E2 (Fig. 1A) , from 1.4-fold change in T-47D to 2.2-fold change in MN1 cells (Supplementary Fig. 1D ). Thus, although p53 mutant proteins are expressed at higher levels than wild-type proteins in basal conditions (CM), E2 manipulation affected both wild-type and mutant proteins levels.
These effects on protein levels were correlated with p53 transcriptional activity on a p53 response-element (RGC, see ''Materials and methods'' section) in MN1 cells using a b-galactosidase reporter assay (Fig. 1E) . b-galactosidase activity was reduced in EF conditions compared to complete medium (CM), and addition of E2 at increasing doses resulted in a dose-dependent increase in reporter activity in MN1 but not in the MDD2 cells that express an inactivated p53 protein (Fig. 1E) . Thus, variations observed in p53 wild-type protein levels upon E2 manipulation correlated with p53 protein activity, showing that estrogens can influence p53 expression and activity.
Overall, these data show that estradiol levels affect both wild-type and mutant p53 protein expression by a mechanism acting at the protein level. E2 deprivation decreased, while E2 treatment increased, p53 protein levels that correlated with p53 transactivation activity.
ERa silencing reduces p53 protein levels
ERa is the main target of estrogens that bind to and activate this receptor. Estrogens are also known to influence ERa
degradation by the proteasome. Withdrawal of estrogens has been shown to cause the accumulation of an inactive ERa protein while the addition of estradiol reinitiate proteasomal degradation and reduce ERa protein levels [24, 25] . As shown in Fig. 1A , ERa protein levels were increased in EF conditions and decreased upon E2 supplementation in all cell lines, as expected. The genomic activity of ERa varied in opposite way (decreased by EF conditions and increased by E2 addition) as assessed by the mRNA expression of the ERa target gene TFF1 that was decreased in EF conditions and increased by E2 addition (Supplementary Fig. 1C) . Thus, the decrease in p53 protein levels observed in EF conditions correlated with an increase in ERa protein that has low genomic activities.
To assess the role of ERa in the reduction of p53 protein levels, ERa was silenced in MN1 and ZR-75-1 cells maintained in CM or EF conditions. Figure 2A shows that ERa siRNA efficiently reduced ERa protein levels and caused a decrease in p53 levels both in the presence ( Fig. 2A, upper panel) or in the absence of E2 ( Fig. 2A, lower panel) . It is of note that in EF conditions, where p53 levels are already low, the reduction upon ERa silencing is very small (1.4-fold change in MN1 and 1.7-fold change in ZR-75-1) compared to the reduction seen in CM (7.1-fold change in MN1 and 8.2-fold change in ZR-75-1) (Supplementary Fig. 1D ). Interestingly, ERa siRNA in CM slightly increased p53 mRNA levels (Fig. 2B) as observed under E2-deprivation (Fig. 1B) . Thus, silencing ERa had similar effects than removing estrogens. It is of note that silencing ERa in the p53 mutated cells BT-474 also reduced p53 protein levels (not shown). These results show that eliminating estrogens, silencing ERa, or both, caused a reduction in basal p53 protein levels, while p53 mRNA levels were slightly increased. This suggests that estrogens affect p53 protein levels through a mechanism that involve E2-liganded ERa.
Estrogen deprivation compromises p53-dependent responses
To address the consequences of reduced p53 levels on DNA damage-induced p53 responses, E2-deprived cells were treated with doxorubicin (DOX). DOX is a chemical inducer of DNA damage and well-known activator of the p53 pathway. Indeed, in CM, treatment with DOX for 24 h induced apoptosis ( Supplementary Fig. 3A) , p53 protein accumulation ( Supplementary Fig. 3B ) and activation of p53 targets (Supplementary Figs. 3B , C) in p53 wild-type but not mutant cell lines, showing that p53 plays a role in DOX-induced apoptosis in these cells. In MN1 and ZR-75-1 cells grown in EF medium, apoptosis induced by DOX was significantly reduced compared to CM condition (Fig. 3A) . DOX-induced levels of p53 protein and its targets, p21 and Mdm2, were also lower in EF conditions compared to CM in both cell lines, although the difference was stronger in MN1 cells than in ZR-75-1 (Fig. 3B) . This reduction in p53 protein level correlated with a significant reduction in the induction of some p53 target genes such as 14.3.3, PUMA and GADD45, as assessed by qRT-PCR (Fig. 3C) . In contrast, the repression of BCL2 and induction of BAX were similar in EF condition and CM in both cell lines (Fig. 3D) .
These results show that estrogen deprivation alters the intensity of the p53 response and compromises the induction of apoptosis induced by doxorubicin in p53 wildtype cells.
Discussion
In this manuscript, we show that estrogen levels act as a rheostat on p53 steady-state levels and impact on p53-dependent responses induced by the DNA-damaging agent DOX. We also provide evidence that this regulation occurs at the protein level and involves the estrogen receptor ERa.
We first show that low levels of estrogens reduced, but high levels increased p53 protein expression and activity. Both wild-type and mutant p53 proteins were affected. These results are in agreement with previous data obtained in MCF-7 and T-47D cell lines [10] . Here, we confirm and extend these observations in other breast cancer cell lines with different p53 status, providing further evidence that estrogen levels affect both wild-type and mutant p53 protein levels in different cellular backgrounds. This effect did not occur at the transcriptional level since p53 mRNA levels were not decreased but even slightly increased in low estrogen conditions in all cell lines. In contrast to previous reports [17, 18] , manipulation of estrogens did not affect p53 sub-cellular distributions in any of the cell lines analyzed here. The reasons are unclear but may be related to differences in culture conditions.
The main target of estrogens is ERa. In the absence of estrogens, it has been reported that ERa may cross-talks with HER2 and impact on p53 stability through Akt/Mdm2 [26] . However, we showed that ERa silencing had similar effects on p53 expression than removing estrogens. It is, thus, not likely that ligand-independent activities of ERa are involved. Instead, a decrease in ERa E2-dependent activities or in E2-liganded ERa protein may be responsible for the decrease in p53 protein expression observed in EF conditions. p53 protein levels are known to be tightly controlled in the cell through proteasome-dependent degradation mediated by Mdm2, one of the p53 target genes [27] . Complexes between p53-ERa, ERa-Mdm2 and p53-Mdm2, as well as ternary complexes between ERa, Mdm2 and p53 have been described that may impact on p53 and ERa stability [7, 28] . In one study, it was suggested that ERa may protect p53 from deactivation by Mdm2 [8] . However, the role of E2 in these interactions remained unclear. Here, we showed that low p53 levels in EF conditions were restored by inhibiting the proteasome. We also observed that inhibition of p53-mdm2 interaction with the small peptide nutlin-3 also restored p53 protein levels in EF conditions (not shown). This suggests that p53 regulation by the proteasome is active and may be enhanced in the absence of estrogens, due to changes in the composition or stoichiometry of ERa-p53-Mdm2 complexes. However, further experiments are needed to investigate this hypothesis. We next addressed the consequences of reduced wildtype p53 protein levels on p53 responses in MN1 and ZR-75-1 cells cultured in EF conditions. First, reduced p53 levels in MN1 cells correlated with reduced activity of a p53RE in a reporter assay. Then, using a DOX treatment to induce a p53 response, we showed that the nuclear accumulation of p53 protein and the induction of classical p53 target genes was lowered in EF medium compared to CM, and this reduction correlated with a reduction in DOXinduced apoptosis. The p53 response seemed to be quantitatively but not qualitatively reduced in EF compared to CM conditions. Since induction of p53 by DNA-damaging treatments such as DOX is known to be due to the stabilization of the protein, our results suggest that lower levels of protein at the start of treatment result in lower levels of activated protein. Lower levels of activated protein result in a reduced p53 response (activation of target genes) that may not be sufficient to induce an apoptotic response. These results are in line with previous reports. One study in MCF-7 cells reported a reduction in DNA damage-induced p53 responses in MCF-7 cells under tamoxifen treatment [31] . Another study provided in vivo evidence of p53 regulation by estrogens in a mouse model. Indeed, it was shown that pre-treatment of BALB/c-p53 wild-type mice with estradiol (alone or with progesterone) increased p53 responses (apoptosis and p21 expression) induced by irradiation and suppressed mammary tumors [29, 30] . Our data, thus, add experimental evidence that regulation of p53 activity by estrogens can impact on anti-cancer treatments. These data are also in line with our previous observation in a large clinical series where the prognostic value of TP53 mutation status was stronger in PR positive cases than in PR negative cases [21] .
The impact of estrogen regulation of p53 mutant proteins remains to be addressed. It has been shown in different cell-based assays as well as in mouse models that p53 mutant proteins may have pro-oncogenic, gain of function activities [32, 33] . However, the molecular determinant of this gain of function activity is still a matter of debate and was thus difficult to address in cell lines. Data obtained in the mouse showed that a mutant protein was regulated in a manner similar to wild-type p53 and was only over expressed in tumor cells [34] . Moreover, its stabilization and over expression was necessary for its gain of function activity. Here, levels of endogenous p53 mutant proteins were also modulated by estrogens, although, in T-47D cells, a longer treatment in EF conditions was required to obtain a significant reduction in p53 levels (not shown). Estrogen stimulation may thus promote high expression levels of mutant proteins that may favor tumorigenesis and treatment resistance through p53 gain of function activities. It would thus be interesting to investigate the regulation of p53 mutant proteins by E2 in mouse models.
In conclusion, this study provides further evidence that estrogens affect p53 levels and function in breast cancer cells and impact on p53-dependent responses to DNA damage. The reduction in p53 activity under low estrogens activity may constitute a general safe guard mechanism to avoid cell death in cells that depend on estrogens for their survival. However, in clinical settings such regulation of p53 activity by estrogens may greatly influence tumor growth and responses to treatments. Specifically designed clinical studies are thus required to further address the clinical relevance of p53 regulation by ERa pathway. For example, it would be important to evaluate in clinical settings the prognostic value of p53 status in patients treated with aromatase inhibitors as, by reducing estrogen levels, they may also reduce p53 anti-proliferative activities.
